New drug shows antiviral benefit against HIV but produces renal side effects

December 19, 1999

An experimental drug that fights the AIDS virus by attacking the enzymes that enable it to replicate has proved effective in a nationwide clinical study.

Named adefovir dipivoxil, the drug reduced viral load-the amount of HIV in the blood-by an average of about 60 percent in patients. Adefovir is an antiretroviral drug known as a nucleotide analog.

The drug was tested in a double-blind trial involving 442 HIV-positive patients at 33 U.S. HIV treatment centers. The study was designed to test the ability of adefovir to produce an effect and its safety.

Study findings are reported in the December 22 issue of the Journal of the American Medical Association. Lead authors are James Kahn, MD, associate professor of medicine at the University of California, San Francisco, and Stephen Lagakos, PhD, chair of the Department of Biostatistics at the Harvard School of Public Health.

Adefovir was developed by Gilead Sciences, Inc., of Foster City, Calif., which sponsored the study. Last month, an advisory panel of the Food and Drug Administration recommended against approval of Gilead's application for the drug. The company has since announced that it will terminate U.S. development of adefovir. An accompanying editorial in JAMA reviews the development of drugs that are effective against drug-resistant HIV and cites the FDA decision.

"We found adefovir to show promise as an HIV medication, particularly in patients whose virus showed resistance to other nucleotide analogs," said Kahn. "Its benefits must be balanced, however, with side effects that were manageable but did involve nausea and other gastro-intestinal problems as well as increasing kidney problems in about 60 percent of the patients over time." Kahn specializes in treating HIV/AIDS patients at the UCSF Positive Health Program based at San Francisco General Hospital Medical Center.

Among other positive results, the drug showed that it remained active when integrated with other antiretroviral drugs in a treatment regimen known as combination therapy. Combination therapy is designed to maximum the medication potency against HIV by striking at a variety of different biochemical mechanisms and at several vulnerable points in the viral lifecycle.

Over the past four years, antiretroviral therapy has led to improved survival for many HIV patients, however, because of the development of resistance, there is an ongoing effort to develop new anti-HIV medications that will add to the drug arsenal for combination therapy, Kahn said. "Every patient is different, so there is no universal combination drug therapy. The combination needs to be adjusted and individually tailored for each patient for optimum benefit. Although adefovir had significant kidney related toxicities, it is still a shame that another treatment option is not going to be available to our patients," said Kahn.

Like other nucleotide analogs, adefovir works by inhibiting a critical enzyme called reverse transcriptase (RT). Current experience in treating HIV patients shows that the best results occur when combination therapy involves drugs that are RT inhibitors-such as adefovir-- along with protease inhibitors or other classes of drugs. The goal of combination therapy is to keep HIV from replicating and then spreading into more cells and to give the body the chance to increase its supply of the infection-fighting CD4+ cells that are destroyed by the virus.

All study participants were treated for at least eight weeks with antiretroviral combination therapy immediately preceding the beginning of the trial. Half the patients received the drug and half received a placebo, an inert substance with no medical benefit. All were encouraged to continue with their antiretroviral regimens. The drug was administered as a pill, taken orally once a day for 24 weeks. At the conclusion of this period, followup screening evaluations continued for another 24 weeks and participants in the adefovir group and placebo group were given the option of continuing with adefovir in their treatment regimen if their health status was appropriate.

In comparison to the reduction in viral load in the adefovir group (about 60 percent or 0.4 log), the level in the placebo group remained constant throughout the study period. Viral load is measured in the number of copies of viral genetic material per milliliter of blood. In both groups, the change in the level of CD4+ cells was not significant.

Participants demonstrating HIV-resistance to other nucleotide analogs- lamivudine or lamivudine in combination with zidovudine-showed "significant benefit" from adefovir, according to study results. More than 75 percent of participants had this resistance at the beginning of the study, and viral load in this group decreased an average of about 70 percent (or 0.5 log) over the 24-weeks.

During the study period, adefovir was associated in some patients with side-effects of elevated liver enzyme levels, gastrointestinal problems, and weight loss. Early indications of kidney dysfunction occurred in about 60 percent of patients who took the drug beyond 24 weeks, but the condition was reversed by stopping adefovir treatment.

These complications were unanticipated, according to the researchers, and should be taken into account in any future use. Findings suggest overall that the drug is useful as an "additional medication for patients who need to build effective treatment combinations to reduce viral replications, but it should be used with close clinical and laboratory monitoring," they write in JAMA.

Co-authors of the JAMA article are Steven Deeks, MD, UCSF Positive Health Program at SFGHMC; Deborah Cherng, MS, and Edmund Ng, PhD, Harvard University; Michael Wulfsohn, MD, PhD, Michael Miller, PhD, Julie Cherrington, PhD, Dean Winslow, MD, John J. Toole, MD, PhD, and Dion Coakley, PharmD, all of Gilead Sciences, Inc.; Avid Hardy, MD, Pacific Oak Research, Beverly Hills; Gildon Beall, MD, Harbor/University of California-Los Angeles Medical Center, Torrance; Richard Cooper, MD, Kraus Medical Partners, Los Angeles; Nesli Basgoz, MD, Massachusetts General Hospital, Boston; and Robert Murphy, MD, Northwestern University Medical School, Chicago.
-end-


University of California - San Francisco

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.